Our Framingham clinics provide a specialized, rapid-acting approach for residents seeking relief from treatment-resistant depression (TRD). Unlike traditional clinical settings, we offer Spravato® (esketamine) nasal spray in a medically supervised, comfortable environment. As an FDA-approved treatment, Spravato is specifically designed for adults who have not found relief through standard oral antidepressants. This allows patients from the MetroWest hub of Framingham to the surrounding communities of Natick, Marlborough, and Milford to access life-changing care without invasive procedures.
Clinical teams in Framingham focus on achieving rapid symptom relief by targeting the brain's glutamate system and NMDA receptors. While traditional antidepressants can take weeks to work, Spravato often begins to alleviate depressive symptoms within hours or days. Our facilities are conveniently located along major MetroWest commuter routes, making them accessible to residents throughout the region without the need to travel into downtown Boston. During your initial consultation, we provide a detailed overview of the esketamine technology to ensure you understand how it targets specific brain pathways associated with mood regulation.
Every Framingham location in the TMS Therapy Near Me directory adheres to rigorous REMS (Risk Evaluation and Mitigation Strategy) safety guidelines. Every treatment course is overseen by licensed psychiatric professionals who monitor patients for at least two hours post-administration to manage potential side effects like dissociation or temporary blood pressure changes.
Clinical teams in Framingham serve the MetroWest area from convenient locations accessible via Route 9 and the Mass Pike corridor. Providing local access to this breakthrough technology helps patients avoid the stress of commuting into Greater Boston. Because Spravato sessions require an in-office stay, our appointment schedules are designed to fit into professional and family routines, making it easier to remain consistent with your care plan.
Yes, Spravato is FDA-approved and has been extensively studied for safety. Because it is administered in a certified clinical setting under the REMS program, patients are monitored by healthcare professionals for at least two hours to manage any temporary side effects like sedation or dissociation.
Yes, our certified Framingham clinics serve as specialized hubs for MetroWest residents, offering access to cutting-edge psychiatric technology in a convenient location serving Natick, Marlborough, Milford, and surrounding towns.
The cost varies based on your individualized plan. Most major Massachusetts insurance providers, including Blue Cross Blue Shield of Massachusetts, Tufts Health Plan, and Harvard Pilgrim, cover Spravato for depression. Our staff will help you verify coverage and explore patient assistance programs that can reduce out-of-pocket costs to as little as $10 per treatment.
Clinical teams typically follows a structured schedule: twice-weekly sessions for the first 4 weeks (Induction), followed by once-weekly sessions for the next 4 weeks (Optimization).
Our Framingham facilities primarily treat adults with Treatment-Resistant Depression (TRD) and Major Depressive Disorder (MDD) with acute suicidal ideation or behavior.
Yes, a referral is generally required to confirm a diagnosis of Treatment-Resistant Depression (TRD), meaning you have not responded to at least two different oral antidepressants.
"*" indicates required fields
